EUROGUIDERM GUIDELINE FOR THE TREATMENT OF PSORIASIS VULGARIS. SYSTEMIC TREATMENT



XII. Abbreviations

AAD	American Academy of Dermatology
ADA	Anti-drug antibodies
ADR	Adverse drug reactions
AE	Adverse event
ANA	Antinuclear antibodies
BCG	Bacillus Calmette-Guérin
BID	Twice daily
BIW	Twice weekly
BSA	Body surface area
CHF	Congestive heart failure
CI	Confidence interval
СКD	Chronic kidney disease
CS	Consensus statement
CSF	Cerebrospinal fluid
CsA	Ciclosporin
CV	Cardiovascular
DMF	Dimethylfumarate
DLQI	Dermatology Life Quality Index
DMARD	Disease-modifying antirheumatic drugs
EDF	European Dermatology Forum
EMA	European Medicines Agency
EOW	Every other week
FUM	Fumarates
GFR	Glomerular filtration rate
GL	Guideline
GRADE	Grading of Recommendations Assessment,
	Development, and Evaluation
HAART	Highly active antiretroviral therapy
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HDL	High-density lipoprotein
HPV	Human papilloma virus
НОМА	Homeostasis Model Assessment
HRQoL	Health-Related Quality of Life
IBD	Inflammatory bowel disease
IFPA	International Federation of Psoriasis Associations
IGRA	Interferon-gamma-release assay
IL	Interleukin
LDL	Low-density lipoprotein
LTBI	Latent tuberculosis infection
MACE	Major adverse cardiac event
MEF	Monoethylfumarate
MI	Myocardial infarction

EUROGUIDERM GUIDELINE FOR THE TREATMENT OF PSORIASIS VULGARIS. SYSTEMIC TREATMENT

	European Dermatology
	Forum

d EBM

MID	Minimal important difference
MS	Multiple sclerosis
MTX	Methotrexate
NMA	Network meta-analysis
NMSC	non-melanoma skin cancer
NSAID	Nonsteroidal anti-inflammatory drugs
NYHA	New York Heart Association
OR	Odds ratio
PASI	Psoriasis Area and Severity Index
РВО	Placebo
PGA	Physician's Global Assessment
PIIINP	Procollagen type III N-terminal peptide
PML	Progressive multifocal leukoencephalopathy
PRAC	Pharmacovigilance Risk Assessment Committee
PsA	Psoriatic arthritis
PUVA	Psoralen plus UV-A
РҮ	Person years
Q2W	Every 2 weeks
Q4W	Every 4 weeks
QD	Once daily
QUICKI	Quantitative Insulin Sensitivity Check Index
QW	Once weekly
RA	Rheumatoid arthritis
RCT	Randomized controlled trial
RPLS	Reversible posterior leukoencephalopathy syndrome
RR	Risk ratio
SAE	Serious adverse event
SmPC	Summary of product characteristics
SR	Systematic review
SUCRA	Surface under the cumulative ranking curve
ТВ	Tuberculosis
TNFi	TNF inhibitor
TST	Tuberculin skin test